Last reviewed · How we verify
BAY86-4980
BAY86-4980 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival.
BAY86-4980 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) that blocks PI3K signaling to suppress tumor cell proliferation and survival. Used for Advanced or metastatic solid tumors with PI3K pathway alterations.
At a glance
| Generic name | BAY86-4980 |
|---|---|
| Sponsor | Bayer |
| Drug class | PI3K inhibitor |
| Target | PI3K (phosphoinositide 3-kinase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PI3K is a key enzyme in cell survival and proliferation pathways frequently dysregulated in cancer. By selectively inhibiting PI3K, BAY86-4980 disrupts downstream signaling through AKT and mTOR, leading to reduced cell growth and increased apoptosis in PI3K-dependent tumors. This mechanism is particularly relevant in cancers with PIK3CA mutations or PTEN loss.
Approved indications
- Advanced or metastatic solid tumors with PI3K pathway alterations
Common side effects
- Hyperglycemia
- Diarrhea
- Rash
- Fatigue
- Nausea
Key clinical trials
- Efficacy of Gynodian® Depot in Women With Impaired Well-being (PHASE3)
- Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY86-4980 CI brief — competitive landscape report
- BAY86-4980 updates RSS · CI watch RSS
- Bayer portfolio CI